Clinical Trial Update: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Pelacarsen (TQJ230) for reducing major cardiovascular events by lowering lipoprotein(a) in patients with cardiovascular disease; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Pelacarsen (TQJ230) (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiovascular Disease and Lipoprotein(a) | Phase 3 | Status: COMPLETED